Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Basal Cell Carcinoma (Basal Cell Epithelioma) – Drugs In Development, 2024 report and make more profitable business decisions.
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include a waxy bump; a scaly, brown, or flesh-colored patch; or a white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.
The Basal Cell Carcinoma (Basal Cell Epithelioma) drugs in development market research report provide comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Basal Cell Carcinoma (Basal Cell Epithelioma) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 59 molecules, with 58 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Basal Cell Carcinoma (Basal Cell Epithelioma) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Activate Therapeutics LLCAiViva BioPharma Inc
Amgen Inc
Aresus Pharma GmbH
Ascend Biopharmaceuticals Ltd
Bayer AG
Biocidium Biopharmaceuticals Inc
Biofrontera AG
Biomed
Bristol-Myers Squibb Co
Coegin Pharma AB
Enkang Pharmaceutical Technology (Guangzhou) Co Ltd
Evotec SE
Feldan Therapeutics Inc
Genentech USA Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
IMVAQ Therapeutics Corp
Ingenew Pharmaceuticals Inc
Institute of Oncology Ljubljana
Invion Ltd
IO Biotech Inc
Kintara Therapeutics Inc
Kintor Pharmaceutical Ltd
Laboratories Ojer Pharma SL
Leo Pharma AS
Mayne Pharma Group Ltd
MedC Biopharma Ltd
Medicenna Therapeutics Corp
Medivir AB
MediWound Ltd
Merck & Co Inc
Moderna Inc
Morphogenesis Inc
Multitude therapeutics Inc
Mustafa Nevzat Ilac ve Kimyevi Maddeler San Tic AS
Neonc Technologies Inc
NuCana Plc
Ono Pharmaceutical Co Ltd
Palvella Therapeutics LLC
Philogen SpA
Promontory Therapeutics Inc
QBiotics Group Ltd
Regeneron Pharmaceuticals Inc
Replimune Ltd
Senhwa Biosciences Inc
Singh Biotechnology LLC
Sirnaomics Ltd
Sol-Gel Technologies Ltd
Turn Therapeutics Inc
Varian Biopharmaceuticals Inc
Verrica Pharmaceuticals Inc
Xencor Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Basal Cell Carcinoma (Basal Cell Epithelioma) reports